Atezolizumab Triplet Induces Intracranial Responses in BRAF V600-Mutated Metastatic Melanoma
Source: Targeted Oncology, September 2022
In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.
The addition of atezolizumab (Tecentriq) to vemurafenib (Zelboraf) plus cobimetinib (Cotellic) for the treatment of patients with BRAF V600-mutated melanoma demonstrated promising intracranial activity in the phase 2 TRICOTEL clinical trial (NCT03625141).
At a median follow-up of 9.7 months (interquartile range, 6.3-15.0 months) the intracranial objective response rate shown in the 65 patients who were BRAF V600 mutation-positive was 42% (95% CI, 29%-54%) by independent review committee (IRC). In the BRAF V600 wild-type cohort of 15 patients, the intracranial ORR was 27% (95% CI, 8%-55%).